Cytopia is developing CYT997, a new anti-cancer agent that disrupts tumour blood vessels. CYT997 is currently being investigated in Phase II clinical trials in a variety of cancers.
Read more
Myeloproliferative disorders (MPDs) are debilitating, and potentially fatal, diseases of blood cell production. Cytopia is developing JAK2 inhibitors for the treatment of myeloproliferative disease, cancer and pulmonary hypertension (PAH). The company's lead drug, CYT387, is expected to enter Ph I clinical trials mid 2009.
Read more
Cytopia is collaborating with Novartis, one of the world's largest pharmaceutical companies to discover and develop new anti-rejection drugs for transplantation. This programme targets JAK3, a key enzyme necessary for the function of white blood cells which mediate transplant rejection.
Read more
23 June 2009
Cytopia lodges IND for JAK2 inhibitor CYT387
16 June 2009
Cytopia secures key patents
5 June 2009
Cytopia moves focus to clinical stage cancer company
29 May 2009
Oral VDA CYT997 - Phase I clinical trial presentation at ASCO
26 May 2009
Cytopia cancer program reaches important milestone
Share Registry
Link Market Services Ltd provide the share registry services to all Cytopia shareholders
Intellectual Property / Patents
Cytopia has a strong and growing intellectual property platform
Annual Reports
Archive of Cytopia's annual reports

To subscribe or unsubscribe to Cytopia email Announcements, please email cytopia@cytopia.com.au with the word 'subscribe' or 'unsubscribe' in the subject line
Copyright © 2009 by Cytopia Ltd. All rights reserved. | Site use and privacy policy